ORIGINAL RESEARCH article
Front. Mol. Neurosci.
Sec. Methods and Model Organisms
Volume 18 - 2025 | doi: 10.3389/fnmol.2025.1671354
Schizophrenia Risk Gene ZNF536 modulates Retinoic Acid Response and Neuronal Gene Networks in SH-SY5Y Cells
Provisionally accepted- 1Mental Health Research Center, Moscow, Russia
- 2FGBUN Institut molekularnoj biologii imeni V A Engel'gardta Rossijskoj akademii nauk, Moscow, Russia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
ZNF536, a brain-specific transcriptional repressor, has recently emerged as a candidate risk gene for schizophrenia (SZ), yet its functional role in human neurodevelopment remains poorly understood. In this study, we used CRISPR/Cas9 genome editing to generate a dual-allelic ZNF536 knockout model in SH-SY5Y cells, combining a 103 kb deletion encompassing SZ-associated intronic regions with a disruption of zinc finger domains in exon 2. Transcriptome profiling of mutant cells undergoing all-trans retinoic acid (ATRA)-induced differentiation revealed impaired activation of retinoic acid receptor (RAR) target genes, reduced neurite outgrowth, and failure of neuronal maturation. Notably, gene set enrichment analysis uncovered dysregulation of E2F4-mediated cell cycle pathways, suggesting that ZNF536 modulates neurogenic commitment through coordinated control of transcriptional repression and cell proliferation. Moreover, the targeted intronic deletion altered the expression of multiple SZ-associated genes, supporting the functional importance of cis-regulatory elements within ZNF536. Together, our results identify ZNF536 as a critical regulator of RA-responsive gene networks and neuronal differentiation, offering new mechanistic insights into its contribution to schizophrenia pathogenesis.
Keywords: ZNF536, Schizophrenia, SH-SY5Y, Retinoic acid, neuronal differentiation, Transcriptome, CRISPR/Cas9, enhancers
Received: 22 Jul 2025; Accepted: 23 Sep 2025.
Copyright: © 2025 Kurishev, Abashkin, Karpov, Marilovtseva, Chaika, Semina and Golimbet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Artemiy O. Kurishev, kurishartt@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.